Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Growth hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  Next»
    Study title: Comparison of 2 beta-blockers(betaxolol and propanolol) on glucagon-stimulation of growth hormone in children - Colle M. Battin J. - 22/07/1983
    Active substance: BETAXOLOL
    Study summary document link (including results):
    View full study record
    Document reference: 41929
    Study title: Combined growth Hormone and Gonadotropin releasing Hormone analogue tretment in adopted girls with precocious or early puberty. Tuvemo et. Al 1998.Combined growth Hormone and Gonadotropin releasing Hormone analogue tretment in adopted girls with precocious or early puberty. Tuvemo et. Al 1998.
    Active substance: Buserelin
    Study summary document link (including results):
    View full study record
    Document reference: 41849
    Study title: Biosynthetic Growth Hormone rhGH by KabiVitrum. Clinical Trial General Guideline
    Active substance: DILTIAZEM
    Study summary document link (including results):
    View full study record
    Document reference: 41743
    Study title: AN 1978153963 19780101. TI Suppression of human growth hormone secretion by cyproheptadine. AU Delitala-G, Devilla-L, Bionda-S, Franca-V. IN Catt. Semeiot. Med. II, Univ. Sassari, Italy. SO Metabolism: Clinical and Experimental {METAB-CLIN-EXP}, 1977, Vol/Iss /Pg. 26/8 (931-936). YR 1977.AN 1978153963 19780101. TI Suppression of human growth hormone secretion by cyproheptadine. AU Delitala-G, Devilla-L, Bionda-S, Franca-V. IN Catt. Semeiot. Med. II, Univ. Sassari, Italy. SO Metabolism: Clinical and Experimental {METAB-CLIN-EXP}, 1977, Vol/Iss /Pg. 26/8 (931-936). YR 1977.
    Active substance: CYPROHEPTADINE
    Study summary document link (including results):
    View full study record
    Document reference: 25251
    Study title: AN 02596504 Medline 20070101. TI Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine. SO American journal of medical genetics, {Am-J-Med-Genet}, Aug 1989, vol. 33, no. 4, p. 457-67, ISSN: 0148-7299. AU Zatz-M, Rapaport-D, Pavanello-R-C, Rocha-J-M, Vainzof-M, Nicolau-W. IN Departamento de Biologia, Universidade de Sao Paulo, Brazil. YR 1989.AN 02596504 Medline 20070101. TI Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine. SO American journal of medical genetics, {Am-J-Med-Genet}, Aug 1989, vol. 33, no. 4, p. 457-67, ISSN: 0148-7299. AU Zatz-M, Rapaport-D, Pavanello-R-C, Rocha-J-M, Vainzof-M, Nicolau-W. IN Departamento de Biologia, Univer...
    Active substance: CYPROHEPTADINE
    Study summary document link (including results):
    View full study record
    Document reference: 25195
    Study title: AN 03794875 Medline 20070101. TI Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. SO The Journal of pediatrics, {J-Pediatr}, Jan 1987, vol. 110, no. 1, p.140-3, ISSN: 0022-3476. AU Kaplowitz-P-B, Jennings-S. YR 1987.AN 03794875 Medline 20070101. TI Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. SO The Journal of pediatrics, {J-Pediatr}, Jan 1987, vol. 110, no. 1, p.140-3, ISSN: 0022-3476. AU Kaplowitz-P-B, Jennings-S. YR 1987.
    Active substance: CYPROHEPTADINE
    Study summary document link (including results):
    View full study record
    Document reference: 25197
    Study title: A STUDY ON THE EFFICACY OF THE COMBINATION OF GROWTH HORMONE AND GONADOTROPIN RELEASING HORMONE ANALOGUES (GNRH-A) ON ADULT HEIGHT IN CHILDREN WITH IDIOPATHIC SHORT STATURE
    Active substance: TRIPTORELIN
    Study summary document link (including results):
    View full study record
    Document reference: 46860
    Study title: STUDY OF THE EFFECT OF TREATMENT WITH LHRH-ANALOGUE (DECAPEPTYL) ALONE OR IN COMBINATION WITH BIOSYNTHETIC HUMAN GROWTH HORMONE (GENOTROPIN) IN ADOPTED CHILDREN WITH EARLY PUBERTY
    Active substance: TRIPTORELIN
    Study summary document link (including results):
    View full study record
    Document reference: 46859
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43355
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43226
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43236
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43246
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994; 79(2):51Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994; 79(2):51
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43317
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43327
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):51Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):51
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43334
    Study title: Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.Metzger DL, Kerrigan JR. Estrogen Receptor Blockade with Tamoxifen Diminishes Growth Hormone Secretion in Boys: Evidence for a Stimulatory Role of Endogenous Estrogens during Male Adolescence. Journal of Clinical Endocrinology and Metabolism 1994;79(2):513-518 1994;(2):513-518.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43345
    Study title: Thomas BC, Stanhope R, Leiper AD. Gonadotropin Releasing Hormone Analogue and Growth Hormone Therapy in Precocious and Premature Puberty following Cranial Irradiation for Acute Lymphoblastic Leukaemia. Hormone Research 1993; 39(1/2):25-29.Thomas BC, Stanhope R, Leiper AD. Gonadotropin Releasing Hormone Analogue and Growth Hormone Therapy in Precocious and Premature Puberty following Cranial Irradiation for Acute Lymphoblastic Leukaemia. Hormone Research 1993; 39(1/2):25-29.
    Active substance: GOSERELIN
    Study summary document link (including results):
    View full study record
    Document reference: 29016
    Study title: Effect of growth hormone on metaphyseal uptake of 99mTc-methylene diphosphonate. Klingensmith WC 3rd, Klingensmith GJ, Tollefsen SE, Schalch DS. J Clin Endocrinol Metab. 1981 Jun;52(6):1162-4.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 44123
    Study title: Combinant human growth hormone improves growth in children receiving glucocorticoid treatment after liver transplantation.Sarna S, Sipilä I, Rönnholm K, Koistinen R, Holmberg C. J Clin Endocrinol Metab. 1996 Apr;81(4):1476-82.
    Active substance: Azathioprine
    Study summary document link (including results):
    View full study record
    Document reference: 49217
    Study title: Randomized study to investigate the effects on growth and the safety of the treatment with recombinant growth hormone in 1 to 2-year-old children with growth retardation due to chronic kidney failure
    Active substance: Somatropin
    Study summary document link (including results): GHCRF-E-2_Norditropin.pdf
    View full study record
    Document reference: 41789
    1  2  3  4  5  6  7  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 09:32:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA